Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) - Total Assets
Based on the latest financial reports, Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) holds total assets worth Rs2.94 Billion INR (≈ $31.79 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Aarey Drugs & Pharmaceuticals Limited debt service capacity to assess how comfortably operating cash covers total debt obligations.
Aarey Drugs & Pharmaceuticals Limited - Total Assets Trend (2009–2025)
This chart illustrates how Aarey Drugs & Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data. See AAREYDRUGS book value for net asset value and shareholders' equity analysis.
Aarey Drugs & Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Aarey Drugs & Pharmaceuticals Limited's total assets of Rs2.94 Billion consist of 89.5% current assets and 10.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.6% |
| Accounts Receivable | Rs1.60 Billion | 67.0% |
| Inventory | Rs454.80 Million | 19.1% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs0.00 | 0.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Aarey Drugs & Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Aarey Drugs & Pharmaceuticals Limited.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aarey Drugs & Pharmaceuticals Limited's current assets represent 89.5% of total assets in 2025, an increase from 75.2% in 2009.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2025, down from 2.6% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 67.0% of total assets.
Aarey Drugs & Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Aarey Drugs & Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Aarey Drugs & Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.82 | 4.64 |
| Quick Ratio | 1.52 | 1.60 | 3.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs1.14 Billion | Rs1.13 Billion | Rs844.78 Million |
Aarey Drugs & Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Aarey Drugs & Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.27 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -21.4% |
| Total Assets | Rs2.38 Billion |
| Market Capitalization | $25.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aarey Drugs & Pharmaceuticals Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aarey Drugs & Pharmaceuticals Limited's assets decreased by 21.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aarey Drugs & Pharmaceuticals Limited (2009–2025)
The table below shows the annual total assets of Aarey Drugs & Pharmaceuticals Limited from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.38 Billion ≈ $25.77 Million |
-21.44% |
| 2024-03-31 | Rs3.03 Billion ≈ $32.80 Million |
+4.11% |
| 2023-03-31 | Rs2.91 Billion ≈ $31.51 Million |
+18.83% |
| 2022-03-31 | Rs2.45 Billion ≈ $26.51 Million |
+5.21% |
| 2021-03-31 | Rs2.33 Billion ≈ $25.20 Million |
+20.07% |
| 2020-03-31 | Rs1.94 Billion ≈ $20.99 Million |
+33.19% |
| 2019-03-31 | Rs1.46 Billion ≈ $15.76 Million |
-14.18% |
| 2018-03-31 | Rs1.70 Billion ≈ $18.36 Million |
+18.51% |
| 2017-03-31 | Rs1.43 Billion ≈ $15.49 Million |
+14.62% |
| 2016-03-31 | Rs1.25 Billion ≈ $13.52 Million |
+8.74% |
| 2015-03-31 | Rs1.15 Billion ≈ $12.43 Million |
+7.54% |
| 2014-03-31 | Rs1.07 Billion ≈ $11.56 Million |
-0.21% |
| 2013-03-31 | Rs1.07 Billion ≈ $11.58 Million |
+23.35% |
| 2012-03-31 | Rs868.36 Million ≈ $9.39 Million |
+103.54% |
| 2011-03-31 | Rs426.64 Million ≈ $4.61 Million |
+63.33% |
| 2010-03-31 | Rs261.20 Million ≈ $2.82 Million |
+69.57% |
| 2009-03-31 | Rs154.04 Million ≈ $1.67 Million |
-- |
About Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl… Read more